Search results
Results from the WOW.Com Content Network
HAART decreases the patient's total burden of HIV, maintains function of the immune system, and prevents opportunistic infections that often lead to death. [2] HAART also prevents the transmission of HIV between serodiscordant same-sex and opposite-sex partners so long as the HIV-positive partner maintains an undetectable viral load. [3]
WHO Disease Staging System for HIV Infection and Disease was first produced in 1990 by the World Health Organization [1] and updated in 2007. [2] It is an approach for use in resource limited settings and is widely used in Africa and Asia and has been a useful research tool in studies of progression to symptomatic HIV disease .
Giving patients a modified gp120 that contains little more than the epitope that both antibodies target could act to "prime" the immune system, followed by a booster that contains trimer spikes in the most natural configuration possible. However, it is still under study whether bNAbs could prevent HIV infection. [6]
In order to foster drug development of new HIV therapies, DAIDS supports research on potential new cellular and viral therapeutic targets and new approaches to validate targets; molecules that could effectively block HIV replication; improved formulation of existing agents; approaches to restore the immune system of HIV-infected individuals ...
By interfering with this process, which is central to the replication of HIV, emtricitabine can help to lower the amount of HIV, or "viral load", in a patient's body and can indirectly increase the number of immune system cells (namely T cells/CD4+ T-cells). Both of these changes are associated with healthier immune systems and decreased ...
Ritonavir, sold under the brand name Norvir, is an antiretroviral medication used along with other medications to treat HIV/AIDS. [4] [5] [8] This combination treatment is known as highly active antiretroviral therapy (HAART). [8] Ritonavir is a protease inhibitor, though it now mainly serves to boost the potency of other protease inhibitors.
Following infection with HIV, the rate of clinical disease progression varies enormously between individuals. Many factors such as host susceptibility and immune function, [2] [3] [4] health care and co-infections, [5] [6] [7] as well as factors relating to the viral strain [8] [9] may affect the rate of clinical disease progression.
The immune system mounts an acute effort to resolve the HIV infection during the seroconversion period. Following this period, the immune system temporarily contains the infection. The symptoms of seroconversion lessen and disappear in most people, with HIV entering a stage of clinical latency. At this stage, the infection remains within the ...